〔Abstract〕 Objective To analyze the risk factors of malignant tumor patients with venous thromboembolism (VTE). Methods A retrospective analysis was conducted on 133 malignant tumor patients treated at the 73rd Army Group Military Hospital from January 2020 to January 2022. The general data of the patients were compared between the malignant tumor group and the malignant tumor combined with VTE group. The risk factors for malignant tumor combined with VTE were identified through multivariate logistic regression analysis, and the one-year mortality rate of the two groups of patients was compared. Results There were statistically significant differences between the two groups in tumor staging, coronary heart disease, chemotherapy, coinfection, hormone therapy, central venous catheterization ratio, and the levels of fibrinogen (FIB), D-dimer (D-D), activated partial thromboplastin time (APTT) and von willebrand factor (vWF) (P < 0.05); The results of multivariate logistic regression analysis showed that tumor stage Ⅲ~Ⅳ presence of coronary heart disease, chemotherapy, infection, hormone therapy, central venous catheterization, and high plasma D-D levels were risk factors for malignant tumors with VTE, and the differences were statistically significant (P < 0.05). The results of multivariate logistic regression analysis showed that tumor stage Ⅲ~Ⅳ, presence of coronary heart disease, chemotherapy, infection, hormone therapy, central venous catheterization, and high plasma D-D levels were risk factors for malignant tumors with VTE (P < 0.05). The one-year mortality rate of patients with malignant tumors combined with VTE was significantly higher than that of patients with malignant tumors, and the difference was statistically significant (P < 0.05). Conclusion Tumor staging Ⅲ~Ⅳ, presence of coronary heart disease, chemotherapy, infection, hormone therapy, central venous catheterization, and high D-D levels are risk factors for malignant tumors with VTE. Early prevention and control measures can be taken according to relevant risk factors in clinical practice to reduce patient mortality.